Daily Cardiology Research Analysis
Three high-impact cardiology studies stood out: an epigenetic multi-omics study identified DNA methylation markers and FKBP5 as mechanistic drivers predicting adverse outcomes in coronary artery disease; a meta-analysis of contemporary RCTs showed no benefit of beta-blockers after MI with preserved ejection fraction while supporting benefit in mildly reduced EF; and a nationwide Danish cohort revealed persistent socioeconomic inequities in long-term survival after new-onset atrial fibrillation.
Summary
Three high-impact cardiology studies stood out: an epigenetic multi-omics study identified DNA methylation markers and FKBP5 as mechanistic drivers predicting adverse outcomes in coronary artery disease; a meta-analysis of contemporary RCTs showed no benefit of beta-blockers after MI with preserved ejection fraction while supporting benefit in mildly reduced EF; and a nationwide Danish cohort revealed persistent socioeconomic inequities in long-term survival after new-onset atrial fibrillation.
Research Themes
- Epigenetic biomarkers and mechanisms in coronary artery disease prognosis
- Reassessment of beta-blockers post-MI by left ventricular ejection fraction
- Socioeconomic inequities driving survival gaps in atrial fibrillation
Selected Articles
1. DNA methylation predicts adverse outcomes of coronary artery disease.
In a multi-center cohort of 933 CAD patients with up to 13-year follow-up, 70 leukocyte DNA methylation sites predicted future death and correlated with inflammatory and cardiac phenotypes. Two CpGs (cg25563198, cg25114611) regulated FKBP5; Fkbp5 knockout reduced infarct size and improved function in mice. A 10-site methylation plus 5-clinical-feature model outperformed clinical models, underscoring translational potential.
Impact: This study links epigenetic markers to both prognosis and mechanism (FKBP5) and validates causality in vivo, advancing risk stratification and target discovery in CAD.
Clinical Implications: DNA methylation panels could augment risk prediction beyond clinical variables in CAD, and FKBP5 represents a mechanistically supported therapeutic target for post-MI remodeling.
Key Findings
- Identified 70 methylation sites associated with future death in 933 CAD patients over up to 13 years.
- Cg25563198 and cg25114611 regulate FKBP5; Fkbp5 knockout reduced infarct size and improved post-MI function in male mice.
- A prognostic model using 10 methylation sites plus 5 clinical features outperformed clinical-only models.
Methodological Strengths
- Multi-center cohort with long-term follow-up and external biological validation.
- Mechanistic triangulation with chromatin accessibility, gene expression, and murine knockout.
Limitations
- Cohort restricted to Chinese CAD patients may limit generalizability.
- Sex-specific effects suggested (male mouse knockout), requiring broader validation.
Future Directions: Validate the methylation panel and FKBP5 pathway across diverse populations and test FKBP5-targeted interventions in translational/clinical studies.
Adverse outcomes including myocardial infarction (MI) and stroke render coronary artery disease (CAD) a leading cause of death worldwide. DNA methylation markers may alert such adversity ahead of the events. We profiled DNA methylation of blood leukocytes in 933 Chinese CAD patients with up-to-13-year follow-up from three centers, identifying 70 differentially methylated sites (DMPs) associated with future death. These DMPs correlated with inflammation markers, left ventricular functions and high-density lipoprotein cholesterol, and impacted gene expression in immune response and cellular scenesence. Notably, cg25563198 and cg25114611 were discovered to regulate FKBP5, whose upregulation persisted during MI and stroke. Fkbp5 knockout in male mice partially rescued MI by reducing infarct size and improving heart function, confirming its critical function. Finally, our prognostic model of 10 methylation sites and 5 clinical features outperformed clinical models. Our study highlights the value of DNA methylation in predicting prognosis in CAD and provides tools for clinical translation.
2. Association between Oral Beta Blocker Therapy and long-term Outcomes after Myocardial Infarction in Individuals with Mildly Reduced or Preserved Left Ventricular Function - a Meta-Analysis of Contemporary Randomized Controlled Trials.
Across 19,826 post-MI patients from contemporary RCTs, oral beta-blockers did not reduce composite events in those with preserved LVEF, whereas patients with mildly reduced LVEF (40–49%) had significantly lower risk (RR 0.76). No sex-based differences were detected.
Impact: Clarifies a long-standing controversy by separating preserved from mildly reduced EF, informing de-escalation in preserved EF and targeted use in mildly reduced EF.
Clinical Implications: For post-MI patients with preserved LVEF, routine beta-blocker continuation beyond the acute phase may be reconsidered; for mildly reduced LVEF, beta-blockers remain beneficial.
Key Findings
- No significant reduction in composite outcome with beta-blockers in preserved LVEF (RR 0.96, 95% CI 0.86–1.08).
- Significant risk reduction in mildly reduced LVEF subgroup (RR 0.76, 95% CI 0.61–0.94).
- No sex-based differences in primary outcome; findings pooled from 19,826 randomized patients with ≥1-year follow-up.
Methodological Strengths
- Systematic review/meta-analysis restricted to contemporary randomized trials.
- Pre-specified subgroup analyses by LVEF category and sex.
Limitations
- Heterogeneity of trial designs and beta-blocker regimens across included studies.
- Event definitions and background therapies may vary; limited data on optimal duration.
Future Directions: Head-to-head RCTs to define optimal duration and patient selection by EF spectrum; pragmatic trials to confirm de-escalation strategies in preserved EF.
BACKGROUND: In the contemporary reperfusion era, the benefit of beta-blocker therapy in patients after acute myocardial infarction (AMI) and preserved left ventricular ejection fraction (LVEF ≥50%) remains unclear. Recently conducted clinical trials have demonstrated mixed results about the clinical benefit of beta-blockers after myocardial infarction in pooled populations of patients with mildly reduced (LVEF 40-49%) or preserved LVEF. However, new evidence suggests a consistent benefit of beta-blocker therapy in patients specifically with mildly reduced LVEF. We aimed to assess the efficacy of beta-blockers in patients with recent myocardial infarction and mildly reduced or preserved LVEF, as well as specifically with preserved LVEF. METHODS: We conducted a systematic review of recent randomized controlled trials that evaluated the effects of oral beta-blocker therapy in patients with AMI who had either mildly reduced LVEF or preserved LVEF and with follow-up data of at least 1 year. Using a Mantel-Haenszel random effects model, we computed risk ratios (RR) with 95% confidence intervals for the primary composite outcome along with individual outcomes of death, re-infarction, and heart failure between patients with and without beta-blocker therapy. We performed analysis of the pooled overall study population, which included patients with mildly reduced LVEF and preserved LVEF, as well as performed subgroup analysis of patients with preserved versus mildly reduced LVEF and among men versus women. RESULTS: 19,826 patients with mildly reduced or preserved LVEF were included in the meta-analysis. Overall, 9,892 patients were assigned to beta-blockers and 9,934 to no beta-blockers. Among the pooled population, we did not demonstrate significant differences between the beta-blocker group and the control group for the primary composite outcome (RR 0.93, 95% CI 0.83-1.04), all-cause death, reinfarction, or heart failure. We further did not detect differences in the primary outcome by sex. While there was no differences in the primary composite outcome among patients with preserved LVEF (RR 0.96, 95% CI 0.86-1.08), there was reduction in risk observed among individuals with mildly reduced LVEF (RR 0.76, 95% CI 0.61-0.94). CONCLUSION: Oral beta-blocker therapy was not associated with a reduction in the primary composite outcome in patients with preserved LVEF. This contrasts with their established benefit in patients with reduced LVEF and the growing evidence of benefit in those with mildly reduced LVEF.
3. Temporal trends in associations between social drivers and life-years lost in newly diagnosed atrial fibrillation in Denmark, 2000-22: a nationwide cohort study.
In 383,566 Danes with new atrial fibrillation, age- and sex-adjusted 10-year restricted mean time lost improved overall from 2000–2010 to 2011–2022, yet inequities persisted: medium vs higher income gaps narrowed slightly, while lower vs higher income gaps slightly widened; education-related inequities showed only small improvements.
Impact: Provides robust, population-scale evidence that social determinants continue to drive survival gaps in AF despite therapeutic advances—critical for policy and care-delivery redesign.
Clinical Implications: Risk stratification and quality metrics in AF should integrate social risk, with targeted outreach, guideline-concordant therapy access, and longitudinal support for disadvantaged groups.
Key Findings
- Among 383,566 newly diagnosed AF patients, overall 10-year life-years lost improved over time.
- Income-related inequities persisted: medium vs higher income gaps slightly narrowed, while lower vs higher income gaps slightly widened between periods.
- Education-based inequities improved modestly; living alone remained an important social driver.
Methodological Strengths
- Nationwide, registry-based cohort with comprehensive capture and long observation window.
- Use of 10-year restricted mean time lost as an absolute, interpretable survival metric across social strata.
Limitations
- Abstract truncation limits visibility of full statistical details (eg, complete p-values) here.
- Observational design is prone to residual confounding despite adjustments.
Future Directions: Test targeted, system-level interventions (eg, navigation, copay support, community AF clinics) to reduce inequities and evaluate effects on survival and complications.
BACKGROUND: Individuals with atrial fibrillation who are systemically disadvantaged often receive lower quality of care and face higher complications and mortality rates. However, data on survival inequity trends are sparse. We examined temporal trends in associations between social drivers and life expectancy loss among individuals with newly diagnosed atrial fibrillation in Denmark. METHODS: In this nationwide, registry-based, cohort study, we assessed mortality in individuals with newly diagnosed atrial fibrillation. Social drivers at diagnosis included family income (lower, medium, higher), educational attainment (lower, medium, higher), and living alone. For each social driver, we compared age-adjusted and sex-adjusted 10-year restricted mean time lost across subgroups as an absolute measure of inequity in expected survival time. Trends were compared between the periods of 2000-10 and 2011-22. FINDINGS: Among 383 566 individuals with newly diagnosed atrial fibrillation, restricted mean time lost improved across all levels of social drivers over time. Life-years lost associated with income changed modestly between periods, with a slight reduction in inequity for people with medium versus higher income (-1·65 years [95% CI -1·70 to -1·60] to -1·55 years [-1·59 to -1·50]), but a slight increase for people with lower versus higher income (-2·46 years [-2·55 to -2·37] to -2·51 years [-2·57 to -2·45]; P